| Oct 21 |
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
|
| Oct 16 |
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
|
| Oct 9 |
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
|
| Sep 11 |
Veru to Present at the 2024 Cantor Global Healthcare Conference
|
| Aug 11 |
Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
| Aug 10 |
Veru Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 10 |
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
|
| Aug 8 |
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
|
| Aug 8 |
Veru GAAP EPS of -$0.07, revenue of $4M
|
| Aug 8 |
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
|
